Univariate and multivariate GEE regression analyses of iNKT/T ratios according to baseline parameters
| Baseline parameters . | Odds ratio (95% CI, modeling the probability that iNKT/T ratio ≥ 10−3 vs < 10−3) . | P . |
|---|---|---|
| Univariate analysis | ||
| Sex | ||
| Male | 1 | |
| Female | 0.52 (0.20-1.38) | .193 |
| Age of recipient, y | ||
| < 45 | 1* | |
| ≥ 45 | 0.30 (0.12-0.78)* | .013* |
| Age of donor, y† | ||
| < 35 | 1* | |
| ≥ 35 and < 45 | 0.20 (0.05-0.77)* | .020* |
| ≥ 45 | 0.43 (0.15-1.19) | .106 |
| Hematologic disease | ||
| AML/ALL/MDS/MPD/AA | 1 | |
| Lymphoma/myeloma | 0.59 (0.22-1.52) | .276 |
| Disease status at transplantation | ||
| CR | 1 | |
| PR or SD | 0.55 (0.21-1.44) | .227 |
| PD | 1.20 (0.19-7.39) | .841 |
| Conditioning regimen | ||
| MAC | 1 | |
| RIC | 2.39 (0.79-7.26) | .121 |
| Donor | ||
| Sibling | 1* | |
| Unrelated (10/10 or 9/10) | 0.29 (0.10-0.78)* | .015* |
| Donor/recipient sex matching | ||
| Female to male | 2.60 (0.90-7.51) | .075 |
| Other | 1 | |
| In vivo T depletion | ||
| No | 1 | |
| Yes | 1.46 (0.58-3.67) | .410 |
| CMV risk | ||
| Low | 1 | |
| Intermediate | 1.08 (0.36-3.22) | .880 |
| High | 1.22 (0.37-4.03) | .737 |
| Type of graft | ||
| BM | 1 | |
| PBMC | 3.48 (0.87-13.94) | .077 |
| Multivariate analysis | ||
| Age, y | ||
| < 45 | 1* | |
| ≥ 45 | 0.21 (0.07-0.59)* | .003* |
| Conditioning regimen | ||
| MAC | 1* | |
| RIC | 3.76 (1.12-12.58)* | .031* |
| Baseline parameters . | Odds ratio (95% CI, modeling the probability that iNKT/T ratio ≥ 10−3 vs < 10−3) . | P . |
|---|---|---|
| Univariate analysis | ||
| Sex | ||
| Male | 1 | |
| Female | 0.52 (0.20-1.38) | .193 |
| Age of recipient, y | ||
| < 45 | 1* | |
| ≥ 45 | 0.30 (0.12-0.78)* | .013* |
| Age of donor, y† | ||
| < 35 | 1* | |
| ≥ 35 and < 45 | 0.20 (0.05-0.77)* | .020* |
| ≥ 45 | 0.43 (0.15-1.19) | .106 |
| Hematologic disease | ||
| AML/ALL/MDS/MPD/AA | 1 | |
| Lymphoma/myeloma | 0.59 (0.22-1.52) | .276 |
| Disease status at transplantation | ||
| CR | 1 | |
| PR or SD | 0.55 (0.21-1.44) | .227 |
| PD | 1.20 (0.19-7.39) | .841 |
| Conditioning regimen | ||
| MAC | 1 | |
| RIC | 2.39 (0.79-7.26) | .121 |
| Donor | ||
| Sibling | 1* | |
| Unrelated (10/10 or 9/10) | 0.29 (0.10-0.78)* | .015* |
| Donor/recipient sex matching | ||
| Female to male | 2.60 (0.90-7.51) | .075 |
| Other | 1 | |
| In vivo T depletion | ||
| No | 1 | |
| Yes | 1.46 (0.58-3.67) | .410 |
| CMV risk | ||
| Low | 1 | |
| Intermediate | 1.08 (0.36-3.22) | .880 |
| High | 1.22 (0.37-4.03) | .737 |
| Type of graft | ||
| BM | 1 | |
| PBMC | 3.48 (0.87-13.94) | .077 |
| Multivariate analysis | ||
| Age, y | ||
| < 45 | 1* | |
| ≥ 45 | 0.21 (0.07-0.59)* | .003* |
| Conditioning regimen | ||
| MAC | 1* | |
| RIC | 3.76 (1.12-12.58)* | .031* |
AA indicates aplastic anemia; ALL, acute lymphoid leukemia; AML, acute myeloid leukemia, CI, confidence interval; CR, complete remission; GEE, generalized estimating equation; HSC, hematopoietic stem cell, invariant natural killer T/T cell; MAC, myeloablative conditioning; MDS, myelodysplasic syndrome; MPD, myeloproliferative disease; PD, progressive disease; PR, partial remission; PBSC, peripheral blood stem cells; and RIC, reduced-intensity conditioning.
Statistically significant.
Age of donor at time of transplantation was arbitrarily divided into tertiles.